GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Urovant Sciences Ltd (NAS:UROV) » Definitions » Tangible Book per Share

Urovant Sciences (Urovant Sciences) Tangible Book per Share : $-4.91 (As of Dec. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Urovant Sciences Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Urovant Sciences's tangible book value per share for the quarter that ended in Dec. 2020 was $-4.91.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Urovant Sciences Tangible Book per Share Historical Data

The historical data trend for Urovant Sciences's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urovant Sciences Tangible Book per Share Chart

Urovant Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20
Tangible Book per Share
0.13 0.24 2.47 -1.89

Urovant Sciences Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -1.89 -2.75 -3.58 -4.91

Competitive Comparison of Urovant Sciences's Tangible Book per Share

For the Biotechnology subindustry, Urovant Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urovant Sciences's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Urovant Sciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Urovant Sciences's Price-to-Tangible-Book falls into.



Urovant Sciences Tangible Book per Share Calculation

Urovant Sciences's Tangible Book Value Per Share for the fiscal year that ended in Mar. 2020 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-58.006-0-0)/30.6353
=-1.89

Urovant Sciences's Tangible Book Value Per Share for the quarter that ended in Dec. 2020 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-145.617-0-14)/32.534
=-4.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Urovant Sciences  (NAS:UROV) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Urovant Sciences Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Urovant Sciences's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Urovant Sciences (Urovant Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Urovant Sciences Ltd is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.
Executives
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Sef Kurstjens director C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Walt Johnston officer: SVP, Commercial, USI UROVANT SCIENCES LTD. 5281 CALIFORNIA AVE SUITE 100 IRVINE CA 92617
Haag-molkenteller Cornelia officer: CMO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Bryan E. Smith officer: GC/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Christine Ocampo officer: PAO;CAO/Urovant Sciences, Inc C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Ajay Bansal officer: PFO;CFO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Robinson James A. Jr. director, officer: PEO;CEO/Urovant Sciences, Inc. 852 WINTER STREET, WALTHAM MA 02451
Sumitomo Chemical Co., Ltd. other: See Footnote (1) 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd other: See Footnote (1) 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Keith Katkin director, officer: PEO;CEO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Shigeyuki Nishinaka director 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617

Urovant Sciences (Urovant Sciences) Headlines

From GuruFocus

RM LAW Announces Investigation of Urovant Sciences Ltd.

By PRNewswire PRNewswire 11-19-2020